Social Behavior – Page 15

Viking Therapeutics Accelerates Obesity Drug Development to Phase 3 Trials

11 months ago talkbio0Tagged competition, GLP-1/GIP receptor agonist, Market, Obesity, Phase 3 trials, Viking, VK2735, Weight Loss

Viking Therapeutics, Obesity Drug, Phase 3 Trials, GLP-1/GIP Receptor Agonist, VK2735, Weight Loss, Market Competition

Novartis Partners with Dren Bio in $3 Billion Deal for Targeted Myeloid Engagers

11 months ago talkbio0Tagged alliance, Billion, biotech, Dosage Forms, Dren, engagers, Myeloid, Novartis

Novartis, Dren Bio, Myeloid Engagers, Biotech, Pharmaceutical, Alliance, $3 Billion Deal

The Best Practice Organization: Key to Success in Today’s Biopharma Industry

11 months ago talkbio0Tagged Anthropological Culture, Best Practice Organization, Biopharma Industry, Business Development, commercial field teams, Generative AI, Leadership, Medical Affairs, Practice Experience, Strategic Workforce Planning, Success Factors, Talent Strategy

Biopharma Industry, Best Practice Organization, Success Factors, Operational Excellence, Business Development Strategy, Talent Strategy, Medical Affairs, Commercial Field Teams, Generative AI, Integrated Teams, Strategic Workforce Planning, Leadership, Culture, Team Dynamics, Talent Experience

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

11 months ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures

AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations

11 months ago talkbio0Tagged appeal, AstraZeneca, Constitutional, drug price, Ira (eukaryote), Mediation, Medicare

AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal

Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?

11 months ago talkbio0Tagged ABC, Anabolism, Avidity Base Chemistry, Aviti sequencer, Biotechnology, Cloudbreak, competition, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Market, SBS, Sequence Analysis

Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

11 months ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

12 months ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)